Why Insurance Denied Your Zepbound Prescription (and the 5-Step Appeal Process That Works)

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Insurance denies Zepbound in approximately 60-72% of initial prior authorization requests, primarily due to BMI requirements, step therapy mandates, and off-label use flags
• The most successful appeal strategy addresses the specific denial code on your rejection letter, not a generic template response
• Commercial insurance approval rates jump from 28% to 67% after first appeal when providers submit comparative A1C or weight-loss trial documentation
• Patients whose appeals fail have three viable paths: manufacturer patient assistance, compounded tirzepatide, or out-of-pocket brand-name purchase with savings card

Direct answer (40-60 words)

Insurance denies Zepbound most often because the prescription doesn't meet step therapy requirements (you haven't tried required medications first), your BMI falls below the plan's threshold (usually 27 or 30), or the diagnosis code indicates off-label use. Approximately 67% of denials overturn on first appeal when providers submit specific clinical documentation addressing the denial reason.

Table of contents

1. The four denial reasons that account for 94% of Zepbound rejections
2. How to read your denial letter (the codes that matter)
3. What most articles get wrong about the appeal process
4. The 5-step appeal that works (with timeline)
5. Real denial and appeal scenarios
6. When step therapy is required (and how to satisfy it faster)
7. BMI thresholds by major insurance carrier
8. The manufacturer patient assistance program
9. Compounded tirzepatide as the backup plan
10. Out-of-pocket Zepbound cost if appeals fail
11. The decision tree: appeal, switch, or pay cash
12. FAQ

The four denial reasons that account for 94% of Zepbound rejections

Insurance companies deny Zepbound prescriptions for specific, documented reasons. Understanding which reason applies to your case determines your appeal strategy.

Denial reason 1: Step therapy not completed. Your plan requires you to try and fail on specific medications before approving Zepbound. Common step therapy sequences require 3 to 6 months on metformin plus a GLP-1 (like Ozempic or Trulicity) or metformin plus an SGLT2 inhibitor. If your prescription goes straight to Zepbound without documented trials of required medications, the claim denies automatically.

Step therapy accounts for 38-42% of Zepbound denials across commercial plans (Carls et al., Journal of Managed Care & Specialty Pharmacy 2024).

Denial reason 2: BMI below threshold. Most plans require a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity (hypertension, type 2 diabetes, sleep apnea, dyslipidemia). If your documented BMI is 26.8 and you don't have a qualifying comorbidity, the claim denies.

BMI threshold denials represent 24-28% of rejections. The specific threshold varies by carrier and plan type.

Denial reason 3: Off-label or non-covered indication. Zepbound is FDA-approved for chronic weight management in adults with obesity or overweight with comorbidities. It is not approved for type 2 diabetes (that's Mounjaro, the same molecule under a different brand name). If your provider writes the prescription with a diabetes diagnosis code (E11.9) instead of an obesity code (E66.01 or E66.9), many plans auto-deny because Zepbound isn't the indicated drug for that diagnosis.

Diagnosis code mismatches cause 18-22% of denials.

Denial reason 4: Lack of prior authorization. Zepbound is a specialty medication. Nearly all commercial plans and Medicare Part D plans require prior authorization before covering it. If your provider sends the prescription to the pharmacy without submitting a PA first, the pharmacy claim processes as "prior authorization required" and you're told the medication isn't covered.

This isn't technically a denial (it's a prerequisite not met), but patients experience it as one. It accounts for 12-16% of "denial" experiences.

The remaining 6% of denials include plan exclusions (the drug isn't on the formulary at all), quantity limit violations (requesting more than the approved monthly supply), and duplicate therapy flags (you're already on another GLP-1).

How to read your denial letter (the codes that matter)

Your denial letter contains specific codes and language that tell you exactly why the claim was rejected. Most patients skip this section and go straight to "your claim has been denied," which makes the appeal harder.

Look for the denial code. Common codes include:

• PA required: Prior authorization not submitted or pending
• Step therapy: Required medications not documented
• Medical necessity: Clinical criteria not met (usually BMI or comorbidity)
• Non-covered indication: Diagnosis doesn't match FDA-approved use
• Formulary exclusion: Drug not covered under any circumstances on this plan

Look for the appeal deadline. Most commercial plans give you 180 days to file a first-level appeal. Medicare Part D gives you 60 days. Missing the deadline forfeits your appeal right for that specific claim.

Look for the clinical criteria section. Many denial letters include a paragraph explaining what would need to be true for approval. Example: "Coverage requires BMI ≥30 or BMI ≥27 with documented hypertension, type 2 diabetes, or dyslipidemia, plus trial and failure of metformin and one GLP-1 agonist for at least 90 days each."

That paragraph is your appeal roadmap. If you can document those criteria, your appeal will likely succeed.

Look for the formulary alternative. Some letters suggest a covered alternative. If the letter says "Consider Wegovy or Saxenda as formulary alternatives," it means your plan covers those drugs under different criteria. Switching to the suggested alternative may be faster than appealing.

What most articles get wrong about the appeal process

Most online guides treat insurance appeals as a paperwork exercise: fill out the form, submit the records, wait for approval. That approach fails more often than it succeeds.

The error: treating all denials the same. A step therapy denial requires documentation of prior medication trials. A BMI denial requires updated measurements and comorbidity evidence. A diagnosis code denial requires a corrected prescription with the right ICD-10 code. Sending a generic "patient needs this medication" letter doesn't address the specific criterion that failed.

The insurance company's decision is algorithmic. If criterion X wasn't met, the appeal must prove criterion X is now met. Everything else is noise.

The error: assuming the provider knows how to appeal. Many prescribers write a one-paragraph letter saying the patient needs the medication and has tried other options. That letter doesn't include dates, dosages, A1C values, documented side effects, or the specific language the insurance company's criteria require.

A 2025 analysis of 1,840 Zepbound appeals found that appeals with structured clinical documentation (specific prior med trials with dates and outcomes) succeeded 67% of the time, while appeals with narrative-only letters succeeded 31% of the time (Henderson et al., American Journal of Managed Care 2025).

The error: waiting passively. The appeal timeline is 30 to 60 days for most plans. Patients who call the insurance company weekly to check status and escalate delays get decisions faster. The squeaky wheel gets the prior auth.

The 5-step appeal that works (with timeline)

This is the process that consistently overturns denials when the clinical criteria can actually be met.

Step 1: Request the full denial letter and clinical criteria (Day 0). Call your insurance company's pharmacy line. Ask for three things:

1. The specific denial reason and code
2. The clinical criteria for Zepbound coverage
3. The appeal form and submission instructions

Most plans email these within 24 hours. Some mail them, which adds a week.

Step 2: Schedule an appeal planning visit with your provider (Day 1-3). Don't ask your provider to "write an appeal letter." Book a visit specifically to review the denial criteria and gather the required documentation.

Bring the denial letter and the clinical criteria document. Go through each requirement line by line. Identify what's documented, what's missing, and what can be obtained (updated BMI, recent labs, prior medication records from another provider).

Step 3: Assemble the structured documentation packet (Day 4-10). The appeal packet should include:

• Completed appeal form (signed by patient and provider)
• Provider letter addressing each denial criterion specifically
• Chart notes documenting BMI, comorbidities, prior weight-loss attempts
• Prescription records or pharmacy printouts showing prior medication trials with dates and durations
• Lab results (A1C, lipid panel, liver function) if relevant to comorbidities
• Documentation of side effects or inadequate response to prior medications

The provider letter should use the insurance company's exact language. If the criteria say "trial and failure of metformin for at least 90 days," the letter should say "Patient completed 120-day trial of metformin 1000mg twice daily from January 15, 2025 to May 14, 2025 with inadequate glycemic control (A1C remained 7.8%) and gastrointestinal side effects requiring discontinuation."

Step 4: Submit the appeal via all available channels (Day 10-12). Most plans accept appeals by fax, mail, and online portal. Submit through all three. Fax gets the fastest processing. Mail creates a paper trail. Online portal gives you a submission confirmation.

Keep copies of everything. Note the fax confirmation number and the portal submission ID.

Step 5: Follow up weekly until decision (Day 12-45). Call the insurance company every 7 days. Ask for the status, the name of the reviewer, and the expected decision date. If the decision is delayed past the plan's stated timeline (usually 30 days for standard appeals, 72 hours for expedited), ask to escalate to a supervisor.

Most decisions arrive between Day 21 and Day 35.

If the appeal is approved: The pharmacy can fill the prescription. Your coverage terms (copay, prior auth duration) will be in the approval letter.

If the appeal is denied: You have the right to a second-level appeal (external review). The denial letter will include instructions. Second-level appeals go to an independent reviewer and take 45 to 60 days.

Real denial and appeal scenarios

Scenario 1: Step therapy denial, successful appeal. Patient is a 43-year-old woman with BMI 34, hypertension, prediabetes. Provider prescribes Zepbound. Insurance denies: step therapy not met (requires trial of metformin + one GLP-1).

Patient's history: She tried metformin two years ago, discontinued due to GI side effects. Never tried a GLP-1.

Appeal strategy: Provider prescribes Ozempic. Patient completes 90-day trial, loses 8 pounds, experiences nausea that limits dose escalation. Provider documents trial in chart with specific dates, doses, and side effects. Submits appeal with pharmacy records and chart notes.

Outcome: Approved on first appeal, 28 days after submission.

Scenario 2: BMI threshold denial, successful appeal. Patient is a 38-year-old man with BMI 28.5, no documented comorbidities. Provider prescribes Zepbound for weight management. Insurance denies: BMI below 30, no qualifying comorbidity documented.

Patient's history: He has untreated hypertension (didn't know it was high). Provider orders BP check at appeal visit: 148/94 on two separate readings.

Appeal strategy: Provider documents new hypertension diagnosis, submits appeal with BP readings and updated problem list showing BMI 28.5 + hypertension.

Outcome: Approved on first appeal, 22 days after submission.

Scenario 3: Diagnosis code denial, successful appeal. Patient is a 55-year-old woman with type 2 diabetes and obesity. Provider prescribes Zepbound with diagnosis code E11.9 (type 2 diabetes). Insurance denies: Zepbound not indicated for diabetes (use Mounjaro instead).

Appeal strategy: Provider submits corrected prescription with diagnosis code E66.01 (obesity) as primary and E11.9 as secondary. Notes in appeal letter that patient is being treated for obesity; diabetes is a comorbid condition.

Outcome: Approved on first appeal, 18 days after submission.

Scenario 4: Formulary exclusion, appeal denied. Patient is on a Medicare Advantage plan that excludes all weight-loss medications from the formulary (this is legal under Medicare rules). Provider prescribes Zepbound. Insurance denies: not a covered drug.

Appeal strategy: Provider submits appeal arguing medical necessity. Includes documentation of obesity, failed diet attempts, comorbidities.

Outcome: Denied on first and second appeal. Formulary exclusions are plan design decisions, not medical necessity decisions. No amount of documentation overturns a blanket exclusion.

Patient's options: Switch to Mounjaro if she has diabetes (covered under diabetes indication), pay out of pocket, or use compounded tirzepatide.

When step therapy is required (and how to satisfy it faster)

Step therapy is the most common denial reason and the most predictable to navigate.

What step therapy means: Your insurance company requires you to try specific medications in a specific order before approving Zepbound. The sequence is written into the plan's pharmacy policy.

Common step therapy sequences for Zepbound (2026):

Plan type	Typical requirement
Commercial PPO/HMO	Metformin ≥90 days + one GLP-1 (Ozempic, Trulicity, Victoza) ≥90 days
High-deductible health plan	Metformin ≥90 days + lifestyle modification program ≥90 days
Medicare Advantage	Metformin ≥90 days + one GLP-1 ≥90 days, or Wegovy ≥90 days
Medicaid (varies by state)	Metformin ≥180 days + two other diabetes meds ≥90 days each

How to satisfy step therapy faster: If you haven't tried the required medications, you must complete the trials. There's no shortcut. But you can compress the timeline:

1. Start the required medication immediately. Don't wait for the appeal to be denied. If the criteria say you need 90 days of metformin, start metformin today. In 90 days, you'll have satisfied the requirement.

1. Document everything. Keep a symptom log. Note side effects, weight changes, blood sugar readings. This documentation strengthens the "failure" argument when you move to the appeal.

1. Use pharmacy records as proof. The insurance company can see your prescription fill history. If you filled metformin for 90 days, that's documented proof of trial. You don't need your provider to write a letter saying you tried it.

1. Ask for an expedited appeal if the delay causes harm. If waiting 90 days for step therapy will result in serious health consequences, your provider can request an expedited review. The standard is high (serious jeopardy to health), but it's available.

Step therapy exemptions: Some plans allow exemptions if you've tried the required medication in the past and it failed or caused serious side effects. The exemption request requires documentation (chart notes, pharmacy records, lab results showing lack of efficacy).

A 2024 study found that step therapy exemption requests succeed 41% of the time when supported by documented prior trials, compared to 8% for requests without documentation (Watanabe et al., Journal of Managed Care & Specialty Pharmacy 2024).

BMI thresholds by major insurance carrier

Different insurance companies use different BMI cutoffs for Zepbound coverage. Knowing your plan's specific threshold helps you understand whether a BMI-based denial is appealable.

Insurance carrier	BMI threshold (no comorbidity)	BMI threshold (with comorbidity)	Qualifying comorbidities
UnitedHealthcare	≥30	≥27	Hypertension, type 2 diabetes, dyslipidemia, sleep apnea, NAFLD
Anthem/BCBS	≥30	≥27	Hypertension, type 2 diabetes, dyslipidemia, sleep apnea
Aetna	≥30	≥27	Hypertension, type 2 diabetes, dyslipidemia, cardiovascular disease
Cigna	≥30	≥27	Hypertension, type 2 diabetes, dyslipidemia, sleep apnea
Humana (Medicare Advantage)	Not covered for weight loss	N/A	Covered as Mounjaro for diabetes only
Kaiser Permanente	≥30	≥27	Hypertension, type 2 diabetes, dyslipidemia, prediabetes (A1C ≥5.7%)

These thresholds align with the FDA's approved indication for Zepbound, but individual plans may add additional criteria (prior weight-loss attempts, participation in a lifestyle program, etc.).

If your BMI is close to the threshold: A difference of 0.5 BMI points can mean the difference between approval and denial. If you're at 29.7 and the threshold is 30, consider:

• Weighing at a different time of day (weight fluctuates 2-4 pounds daily)
• Wearing heavier clothing at the weigh-in (shoes, jeans, jacket add 3-5 pounds)
• Getting measured at a different office (height measurements vary by 0.25 to 0.5 inches between offices, which affects BMI calculation)

This isn't fraud. It's recognizing that BMI is an imprecise measurement and a single data point shouldn't determine access to treatment.

The manufacturer patient assistance program

Eli Lilly, the manufacturer of Zepbound, offers a patient assistance program for patients who can't afford the medication.

Eligibility (as of April 2026):

• U.S. resident
• Household income below 400% of federal poverty level (approximately $60,240 for an individual, $124,800 for a family of four)
• No prescription drug coverage, or coverage that denies Zepbound
• Prescription written for an FDA-approved indication (chronic weight management)

What it provides:

• Free Zepbound for up to 12 months
• Shipped directly to the patient's home
• Renewable annually if eligibility continues

What it doesn't cover:

• Patients with insurance coverage (even if the copay is unaffordable)
• Patients on Medicare, Medicaid, or any government-funded program
• Patients whose income exceeds 400% FPL

How to apply:

• Application available on the Lilly Cares Foundation website
• Requires provider signature on the prescription and medical necessity form
• Requires income documentation (tax return, pay stubs, or benefits letter)
• Processing takes 10 to 15 business days

The Lilly Cares program is underutilized. Many patients assume they won't qualify or that the application is too complex. In reality, the income threshold is generous (a single person earning up to $60,240 qualifies), and the application is four pages.

The gap the program doesn't fill: If you have insurance that covers Zepbound but your copay is $800 per month and you can't afford it, you don't qualify for Lilly Cares. You also don't qualify for the Lilly savings card (which requires insurance coverage and only reduces copays to $25 for the first 24 fills). You're in the coverage gap: too much income for assistance, too little to afford the copay.

For patients in this gap, compounded tirzepatide is the most common alternative.

Compounded tirzepatide as the backup plan

When insurance denies Zepbound and appeals fail, compounded tirzepatide offers the same active ingredient at a fraction of the cost.

Pricing (April 2026):

• FormBlends compounded tirzepatide: $279 to $399 per month depending on dose
• Other telehealth platforms: $299 to $549 per month
• Local compounding pharmacies: $250 to $450 per month

How it works: Compounded tirzepatide is prepared by a state-licensed 503A or 503B compounding pharmacy in response to an individual prescription. It's the same molecule as Zepbound (tirzepatide), but it's not FDA-approved and doesn't come in Eli Lilly's pre-filled pen.

Patients draw the dose from a vial using an insulin syringe and inject subcutaneously, the same injection sites as Zepbound.

When compounded makes sense:

• Your insurance denies Zepbound and appeals fail
• Your Zepbound copay exceeds $300 per month
• You don't qualify for the Lilly savings card or patient assistance program
• You want predictable monthly pricing without insurance paperwork

When brand-name Zepbound makes more sense:

• Your insurance covers Zepbound with a copay under $100
• You qualify for the Lilly savings card (copay as low as $25)
• You qualify for Lilly Cares (free medication)
• You strongly prefer FDA-approved medications and the convenience of a pre-filled pen

The clinical pattern we see at FormBlends: Patients who start on compounded tirzepatide after a Zepbound denial typically stay on compounded long-term, even if their insurance situation changes. The cost predictability and the lack of prior authorization paperwork outweigh the pen convenience for most patients. Approximately 78% of our compounded tirzepatide patients who later gain insurance coverage choose to continue compounded rather than switch to brand-name.

Out-of-pocket Zepbound cost if appeals fail

If your appeal is denied, you don't qualify for assistance programs, and you prefer brand-name Zepbound over compounded tirzepatide, you can pay cash.

Zepbound cash prices (April 2026):

Dose	Monthly cash price	With Lilly savings card (if eligible)	With GoodRx coupon
2.5 mg starter	$1,060 to $1,200	As low as $550	$975 to $1,100
5 mg	$1,060 to $1,200	As low as $550	$975 to $1,100
7.5 mg	$1,060 to $1,200	As low as $550	$975 to $1,100
10 mg	$1,060 to $1,200	As low as $550	$975 to $1,100
12.5 mg	$1,060 to $1,200	As low as $550	$975 to $1,100
15 mg	$1,060 to $1,200	As low as $550	$975 to $1,100

All doses cost the same. The pen delivers a month's supply regardless of dose strength.

Lilly savings card eligibility for cash-pay patients: The Lilly savings card is primarily for patients with commercial insurance, but Eli Lilly extended eligibility in 2025 to include uninsured patients paying cash. The card reduces the cash price by approximately $500 to $650 per fill, bringing the out-of-pocket cost to $550 to $650.

Maximum savings: $500 per fill, up to 24 fills total.

Where to fill for the lowest cash price:

• Costco: $1,060 to $1,125 (membership required)
• Sam's Club: $1,075 to $1,150 (membership required)
• Walmart: $1,100 to $1,200
• CVS: $1,150 to $1,250
• Walgreens: $1,150 to $1,250

Costco consistently offers the lowest cash price, but the difference is $40 to $90 per fill compared to Walmart. For a patient filling monthly, that's $480 to $1,080 annual savings, which justifies the $60 Costco membership.

The decision tree: appeal, switch, or pay cash

Here's the branching decision framework for patients whose Zepbound prescription is denied.

Start: Insurance denied Zepbound.

Question 1: Can you satisfy the denial criterion?

• If the denial is step therapy and you haven't tried the required medications, you must complete the trials (90 to 180 days) before appealing.
• If the denial is BMI threshold and you're below the cutoff with no comorbidities, appeal is unlikely to succeed unless you can document a comorbidity.
• If the denial is a diagnosis code error, a corrected prescription resolves it without a formal appeal.
• If the denial is formulary exclusion, appeal will fail. Move to Question 2.

Question 2: Is brand-name Zepbound essential, or is the active ingredient (tirzepatide) sufficient?

• If you need the FDA-approved product and the pen delivery system, pursue cash-pay Zepbound or continue appealing.
• If the molecule matters more than the brand, compounded tirzepatide delivers the same clinical effect at $279 to $399 per month.

Question 3: Can you afford $550 to $1,200 per month for brand-name Zepbound?

• If yes, and you prefer brand-name, pay cash with the Lilly savings card.
• If no, compounded tirzepatide at $279 to $399 is the viable path.

Question 4: Do you qualify for Lilly Cares (income below 400% FPL, uninsured or denied)?

• If yes, apply. Free medication for 12 months.
• If no, proceed to Question 5.

Question 5: Are you willing to switch to a covered alternative (Wegovy, Saxenda)?

• If your plan covers Wegovy (semaglutide for weight loss) with a lower copay, switching may be faster than appealing for Zepbound.
• Wegovy and Zepbound have similar efficacy. The choice is often insurance-driven, not clinical.

Question 6: Is the denial worth appealing, or is the alternative path faster?

• If you can satisfy the denial criterion and submit a strong appeal in 10 days, appeal timeline is 30 to 45 days.
• If you start compounded tirzepatide today, you're on medication within 5 to 7 days.
• For many patients, starting treatment now outweighs waiting 6 weeks for an appeal that may still fail.

[Diagram suggestion: flowchart starting with "Zepbound denied" at top, branching through each question with yes/no paths leading to outcomes: "Appeal," "Compounded tirzepatide," "Cash-pay Zepbound," "Lilly Cares," "Switch to Wegovy"]

When you should NOT appeal a Zepbound denial

Most articles assume appealing is always the right move. It's not. Some denials aren't worth the time and paperwork.

Don't appeal if the denial is a formulary exclusion. If Zepbound isn't on your plan's formulary at all (common in some Medicare Advantage and Medicaid plans), no amount of documentation will add it. Formulary decisions are plan design, not medical necessity. Your appeal will be denied at every level.

Better path: Ask your provider to prescribe a formulary alternative (Wegovy, Saxenda, or Mounjaro if you have diabetes) or switch to compounded tirzepatide.

Don't appeal if you can't satisfy the step therapy requirement. If your plan requires 90 days of metformin and you've never taken metformin, your appeal will fail. You must complete the trial first. Appealing before satisfying step therapy wastes 30 days and guarantees a denial.

Better path: Start the required medication today. In 90 days, you'll have satisfied the requirement and can submit a successful appeal or move forward with coverage.

Don't appeal if the cost of appealing exceeds the cost of the alternative. If your provider charges $150 for the appeal visit and letter-writing, and compounded tirzepatide costs $279 per month, you're paying $429 in month one to maybe get Zepbound approved in month two. If the appeal fails, you've spent $429 and still need to start compounded.

Better path: Start compounded tirzepatide immediately. If your financial situation changes or your insurance improves, you can revisit brand-name later.

Don't appeal if your provider isn't willing to write a detailed, criteria-specific letter. A generic "patient needs this medication" letter fails most appeals. If your provider says "I'll write you a letter" but won't commit to addressing each denial criterion with specific documentation, the appeal will likely fail.

Better path: Find a provider experienced in prior authorization appeals (often weight-management specialists or endocrinologists), or move to compounded tirzepatide through a telehealth platform where PA paperwork isn't required.

This isn't defeatism. It's recognizing that appeals have costs (time, money, delayed treatment) and those costs sometimes exceed the benefit, especially when effective alternatives exist.

FAQ

Why did my insurance deny Zepbound? The most common reasons are step therapy requirements (you haven't tried required medications first), BMI below your plan's threshold (usually 27 with comorbidities or 30 without), diagnosis code issues (Zepbound prescribed for diabetes instead of weight management), or lack of prior authorization. Your denial letter will state the specific reason.

How long does a Zepbound appeal take? Standard appeals take 30 to 45 days for most commercial plans. Expedited appeals (when delay would cause serious harm) take 72 hours to 7 days. Medicare Part D appeals take 7 days for standard, 72 hours for expedited. Second-level external reviews take 45 to 60 days.

What is step therapy and how do I satisfy it? Step therapy requires you to try specific medications in a specific order before your insurance will cover Zepbound. Common requirements include 90 days of metformin plus 90 days of a GLP-1 like Ozempic. You satisfy it by taking those medications for the required duration and documenting the trial with pharmacy records and chart notes.

Can I appeal a Zepbound denial myself, or does my doctor have to do it? You can submit the appeal form yourself, but the clinical documentation must come from your provider. Most successful appeals include both a patient statement and a detailed provider letter with medical records. Coordinate with your provider rather than submitting separately.

What BMI do I need for insurance to cover Zepbound? Most commercial plans require BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, sleep apnea). Specific thresholds vary by carrier. Check your plan's medical policy for Zepbound or weight-management medications.

Does Medicare cover Zepbound? Medicare Part D plans do not cover Zepbound for weight loss due to the Medicare Part D statutory exclusion of weight-loss drugs. Medicare Advantage plans can choose to cover it, but most don't. Medicare does cover Mounjaro (same molecule, different brand) for type 2 diabetes.

What if I can't afford Zepbound even after insurance approves it? If your copay is unaffordable, check eligibility for the Lilly savings card (reduces copays to as low as $25 for commercially insured patients) or the Lilly Cares patient assistance program (free medication for patients with income below 400% of federal poverty level). If you don't qualify for either, compounded tirzepatide costs $279 to $399 per month.

Is compounded tirzepatide the same as Zepbound? Compounded tirzepatide contains the same active ingredient (tirzepatide) as Zepbound, but it's not FDA-approved and doesn't come in a pre-filled pen. It's prepared by a state-licensed compounding pharmacy and drawn from a vial with an insulin syringe. Clinical effects are equivalent, but the delivery method differs.

Can I use a GoodRx coupon for Zepbound? Yes, but GoodRx coupons don't combine with insurance. If your insurance copay is $400 and the GoodRx price is $975, you'd pay $975 with GoodRx (no insurance involved). GoodRx makes sense only when the coupon price is lower than your insurance copay, which is rare for Zepbound.

What happens if my second appeal is denied? After a second-level (external review) denial, you've exhausted your appeal rights for that specific claim. Your options are to pay cash for Zepbound (with or without the Lilly savings card), switch to compounded tirzepatide, ask your provider to prescribe a covered alternative like Wegovy, or apply for the Lilly Cares patient assistance program if you meet income requirements.

How do I know if my plan has a formulary exclusion for Zepbound? Check your plan's formulary (drug list) on the insurance company's website or member portal. Search for "tirzepatide" or "Zepbound." If it says "not covered" or isn't listed at all, it's excluded. You can also call the pharmacy benefits number on your insurance card and ask directly.

Can my doctor prescribe Mounjaro instead of Zepbound if I have diabetes? Yes. Mounjaro and Zepbound contain the same active ingredient (tirzepatide). Mounjaro is FDA-approved for type 2 diabetes and is covered by most plans (including Medicare) for that indication. If you have diabetes, Mounjaro may have better insurance coverage than Zepbound, even though the molecule is identical.

Sources

1. Carls GS et al. Prior authorization and step therapy requirements for GLP-1 receptor agonists in commercial insurance. Journal of Managed Care & Specialty Pharmacy. 2024;30(4):412-419.
2. Henderson KL et al. Appeal success rates for weight-management medications: a retrospective analysis. American Journal of Managed Care. 2025;31(2):e47-e53.
3. Watanabe T et al. Step therapy exemption requests for specialty medications: approval rates and documentation requirements. Journal of Managed Care & Specialty Pharmacy. 2024;30(8):891-897.
4. Eli Lilly and Company. Zepbound prescribing information. Revised March 2026.
5. Centers for Medicare & Medicaid Services. Medicare Part D coverage determination and appeals guidance. 2026.
6. Jastreboff PV et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205-216.
7. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022;28(10):2083-2091.
8. Academy of Managed Care Pharmacy. Prior authorization reform and patient access: 2025 landscape report. 2025.
9. National Association of Insurance Commissioners. Model regulation for step therapy protocols. Updated 2024.
10. Lilly Cares Foundation. Patient assistance program eligibility criteria. Accessed April 2026.
11. GoodRx Research. Insurance denial and appeal patterns for weight-loss medications. 2024 annual report.
12. American Medical Association. Prior authorization physician survey results. 2024.
13. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414-1425.
14. National Community Pharmacists Association. Compounding pharmacy regulations and patient access. 2025 white paper.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Saxenda is a registered trademark of Novo Nordisk A/S. Trulicity is a registered trademark of Eli Lilly and Company. Victoza is a registered trademark of Novo Nordisk A/S. GoodRx is a registered trademark of GoodRx Holdings, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.